

Adrenal Insufficiency Committee meeting 4

Date: 12 October 2022

Location: Virtual meeting

Minutes: Final

Committee members present:		
Benjamin Ellis (BE)		(Present for items 1 – 9)
Helen Simpson (HS)		(Present for items 1 – 9)
Anh Tran (AT)		(Present for items 1 – 9)
Kate Owen (KO)		(Present for items 1 – 9)
Chloe Mezzetti (CM)		(Present for items 1 – 9)
Colin Omorodion (CO)		(Present for items 1 – 9)
Kate Davies (KD)		(Present for items 1 – 9)
Kaz Williams (KW)		(Present for items 1 – 9)
Lisa Shepherd (LS)		(Present for items 1 – 9)
Sally Tollerfield (ST)		(Present for items 5 – 9)
Philip Newland-Jones (PNJ)		(Present for items 1 – 9)
Simon Pearce (SP)		(Present for items 1 – 9)

In attendance:		
Alexandra Bonnon (AB)	Health economist	(Present for items 1 – 9)
Benjamin Fletcher (BF)	Technical Analyst, Surveillance Team	(Present for items 1 – 9)
Catrina Charlton (CC)	Guideline Commissioning Manager	(Present for items 1 – 9)
Maheen Qureshi (MQ)	Research Fellow	(Present for items 1 – 9)
Meena Tafazzoli (MT)	Technical Analyst	(Present for items 1 – 9)
Patrick Langford (PL)	Technical Analyst, Surveillance Team	(Present for items 1 – 9)
Catharine Baden-Daintree (CBD)	Senior Editor	(Present for items 1 – 9)
Saoussen Ftouh (SF)	Senior Research Fellow	(Present for items 1 – 9)
Sharon Swain (SS)	Guideline Lead	(Present for items 1 – 9)
Sophia Kemmis-Betty	Health Economics Lead	(Present for items 1 – 9)
Stephen Deed (SD)	Information Specialist	(Present for item 8)
Tamara Diaz (TD)	Project Manager	(Present for items 1 – 9)

Apologies:

Nabil Boulos (NB)
Ranna El Khairi (RK)

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourth meeting on the Adrenal Insufficiency guideline. Apologies are noted above. The Committee members were introduced to new members of the technical team and the Senior Medical Editor.

The Chair outlined the objectives of the meeting, which included presentation of the results of the evidence reviews on:

- DHEA for primary and secondary Adrenal Insufficiency
- Glucocorticoids for primary Adrenal Insufficiency (non-CAH)
- Pharmacological treatments for the emergency management of adrenal crisis

And, the discussion of the review protocols for the following questions:

- 5.1. What ongoing care and monitoring should be offered to people with adrenal insufficiency?
- 5.2. What ongoing care and monitoring should be offered to people with adrenal insufficiency who are receiving end of life care?

2. Confirmation of matter under discussion, and declarations of interest

New declarations made by committee members on meeting day are listed below.

Name	Declaration	Classification	Action
Chloe Mezzetti	Employee at Addison's Disease self-help group from 01 09 2022.	Direct Financial Specific	Declare and participate
Sally Tollerfield	Joining an advisory board to look at a prototype for a new updated growth hormone administration device for a company (Merck), product we already use at GOSH.	Direct Financial Nonspecific	Declare and participate
	Offered support by two pharma companies to be able to attend the BSPED meeting at the beginning of November. Presenting a poster on dissertation and a BSPED poster with	Direct Financial Nonspecific	Declare and participate

	one of the Scottish CNS' on the family information for the paediatric adrenal insufficiency group (PAIG).		
<p>The Chair and a senior member of the Developer's team noted that the interests noted on the circulated register and those listed above, would not prevent attendees from fully participating in meeting discussions.</p>			
<p>3. Confirmation of minutes</p>			
<p>Minutes of guideline committee meeting 3 were confirmed, pending an edit to the attendees list. Rebecca Boucher was added to the list of attendees.</p>			
<p>4. Update on recruitment</p>			
<p>The committee heard that recruitment efforts continue for outstanding committee roles.</p>			
<p>5. Evidence review: DHEA for primary, secondary and tertiary AI</p>			
<p>The clinical evidence for the following questions were presented for the group's consideration, specifically related to the use of Dehydroepiandrosterone:</p> <ul style="list-style-type: none"> • What is the clinical and cost effectiveness of pharmacological treatments for the routine management of primary adrenal insufficiency? • What is the clinical and cost effectiveness of pharmacological treatments for the routine management of secondary and tertiary adrenal insufficiency? <p>There was no economic evidence for this review. Recommendations were drafted for this topic, after the committee's discussion of the evidence.</p>			
<p>6. Evidence review: Glucocorticoids for primary AI (non-CAH)</p>			
<p>The clinical and economic evidence for the following question were presented for the group's consideration, specifically related to the use of Glucocorticoids:</p> <ul style="list-style-type: none"> • What is the clinical and cost effectiveness of pharmacological treatments for the routine management of primary adrenal insufficiency? <p>The economic evidence presented for this review included unit cost analysis. Recommendations were drafted for this topic, after the committee's discussion of the clinical and economic evidence.</p>			
<p>7. Evidence review: Pharmacological treatments for the emergency management of adrenal crisis.</p>			

There was no clinical evidence for this review. The economic evidence related to unit costs for this area was presented for the following question:

- What is the clinical and cost effectiveness of pharmacological treatments for the emergency management of adrenal crisis?

The group discussed the evidence presented and the possibility of considering evidence in the form of other guidelines for this clinical area.

8. Draft protocols:

The committee discussed and drafted the review protocol for the following clinical question:

5.1. What ongoing care and monitoring should be offered to people with adrenal insufficiency?

Due to time constraints the following draft question will be deferred for discussion at a later committee meeting:

5.2. What ongoing care and monitoring should be offered to people with adrenal insufficiency who are receiving end of life care?

9. Any other business

None.

Date of next meeting: 30 November 2022

Location of next meeting: Virtual meeting